contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


invitation-to-presentation-of-q-lineas-year-end-report-q4-2024-on-february-28-2025

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Q-Linea operates in the medical technology sector. The company specializes in research and development of instruments and consumables. The products are mainly used in the treatment of infectious diseases and blood poisoning, and include diagnostic and analytical tools, as well as basic sample handling. The technology is based on the so-called ID and AST technology. Q-Linea was founded in 2008 and is headquartered in Uppsala.

Q-Linea

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), published the company’s Year-end report for the period January – December 2024 on Friday 28 February 2025, at 07:30 a.m. (CEST).Q-linea invites ...

<div class="mfn-preamble"><p><strong>Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), published the company’s Year-end report for the period January – December 2024 on Friday 28 February 2025, at 07:30 a.m. (CEST).</strong></p></div><div class="mfn-body"><p>Q-linea invites investors, analysts and the media to an audiocast and teleconference (in English) today,<br>28 February 2025, at 1:00 to 2:00 p.m. (CEST). CEO Stuart Gander and CFO Christer Samuelsson will present Q-linea, comment on the year-end report for 2024 financial year and respond to questions.<br>To participate via webcast, please visit the following link: <a rel="noopener" href="https://q-linea.events.inderes.com/q4-report-2024">https://q-linea.events.inderes.com/q4-report-2024</a></p><p>There will be an opportunity to ask questions in writing at the webcast.</p><p>If you would like to ask questions verbally via conference call, please register at the following link:<br><a rel="noopener" href="https://events.inderes.com/q-linea/q4-report-2024/dial-in">https://events.inderes.com/q-linea/q4-report-2024/dial-in</a></p><p>You will receive a telephone number and a meeting ID to log into the conference call after registering. There will be an opportunity to ask questions verbally during the conference call.</p></div><div class="mfn-footer mfn-contacts mfn-828219978778"><p><strong class="mfn-heading-1">For more information, please contact:</strong></p><hr><p>Stuart Gander, President &amp; CEO, Q-linea <br><a rel="noopener" href="mailto:stuart.gander@qlinea.com">Stuart.Gander@qlinea.com</a><br>+1 857 409 7463</p><p>Christer Samuelsson, CFO /IR, Q-linea AB<br><a rel="noopener" href="mailto:Christer.Samuelsson@qlinea.com">Christer.Samuelsson@qlinea.com</a><br>+46 (0) 70-600 15 20<br></p></div><div class="mfn-footer mfn-about mfn-2048cb62925b"><p><strong class="mfn-heading-1">About Q-linea</strong></p><hr><p>Q-linea’s rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.<br>Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.<br>ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/b9684245-fc0f-405b-a462-279b589496c2/invitation-to-presentation-of-q-lineas-year-end-report-q4-2024-on-february-28-2025.pdf" class="mfn-generated mfn-primary">Invitation to presentation of Q-linea’s Year-end report Q4-2024 on February 28, 2025</a></p></div>

Invitation to presentation of Q-linea’s Year-end report Q4-2024 on February 28, 2025